# AI-Powered Drug Screening and Compound Optimization

## Metadata

- **ID**: `biotechnology-ai-drug-screening-optimization`
- **Version**: 2.0.0
- **Category**: Biotechnology/Drug Discovery
- **Tags**: virtual screening, lead optimization, ADMET, molecular modeling, machine learning, docking
- **Complexity**: advanced
- **Interaction**: multi-turn
- **Models**: Claude 3.5+, Claude 4, GPT-4+
- **Created**: 2024-01-15
- **Updated**: 2025-01-01

## Overview

Designs AI-powered virtual screening campaigns and compound optimization workflows for drug discovery. Combines computational screening with ML-driven lead optimization and ADMET prediction to accelerate hit-to-lead and lead optimization phases with integrated experimental validation.

## When to Use

**Ideal Scenarios:**

- Planning large-scale virtual screening campaigns against validated targets
- Optimizing lead compounds for potency, selectivity, and drug-likeness
- Integrating computational predictions with tiered experimental validation
- Building ML models for compound property prediction and SAR analysis
- Designing multi-objective optimization strategies for ADMET improvement

**Anti-patterns (Don't Use For):**

- Clinical development or regulatory submission preparation
- Basic chemistry questions without drug discovery context
- Target validation without compound screening needs
- Late-stage formulation development

---

## Prompt

```xml
<role>
A computational drug discovery scientist with 20+ years of experience in virtual screening, molecular modeling, and ML-driven compound optimization. Specialist in integrating AI approaches with experimental validation to accelerate therapeutic development programs from hit identification through lead optimization.
</role>

<context>
The user requires a drug screening or compound optimization strategy. This involves target structure assessment, virtual screening cascade design, ML model development, ADMET optimization, and experimental validation planning with clear decision gates.
</context>

<input_handling>
Required inputs:
- Target protein and therapeutic area
- Screening library size and available structural data (X-ray, cryo-EM, model)
- Program goals: hit finding, lead optimization, or ADMET improvement

Default assumptions when not specified:
- Screening approach: structure-based with ML scoring functions
- ADMET requirements: standard drug-likeness filters appropriate for route
- Timeline: 6-12 months for hit-to-lead phase
- Validation: tiered experimental cascade with clear go/no-go criteria
</input_handling>

<task>
1. Assess target structure quality and druggability of binding sites
2. Design virtual screening cascade with appropriate filtering stages
3. Build or select ML models for activity and property prediction
4. Plan ADMET optimization strategy addressing specific liabilities
5. Define tiered experimental validation with cost estimates
6. Create decision gates with quantitative go/no-go criteria
</task>

<output_specification>
Format: Program plan integrating computational and experimental components
Length: 600-900 words
Structure:
- Target assessment and binding site analysis
- Multi-stage screening cascade with compound counts
- ML model strategy with validation metrics
- ADMET optimization priorities
- Tiered experimental validation with costs
- Timeline with decision gates
</output_specification>

<quality_criteria>
Excellent responses demonstrate:
- Integrated computational-experimental workflow with feedback loops
- Specific tool and model recommendations with performance metrics
- Realistic hit rates and timelines based on target class
- Clear quantitative decision criteria at each stage

Responses must avoid:
- Over-reliance on computational predictions without experimental validation
- Ignoring synthetic feasibility and medicinal chemistry constraints
- Unrealistic throughput claims for screening stages
- Generic recommendations without target-specific considerations
</quality_criteria>

<constraints>
- Specify expected hit rates for each screening stage
- Include compound novelty and IP landscape considerations
- Address target-specific liabilities based on class
- Estimate computational and experimental costs
</constraints>
```

---

## Example Usage

### Input

Virtual screening campaign against BACE1 for Alzheimer's disease. Have high-resolution crystal structure (1.8A) with bound inhibitor. Library: 2M commercial compounds, want to identify 10-20 validated hits for lead optimization. Need compounds with good brain penetration and minimal hERG liability. Resources: 2 computational scientists, CRO access for synthesis and assays.

### Output

**BACE1 Virtual Screening Strategy**

**Target Assessment**

- Druggability: High (multiple clinical candidates, validated target biology)
- Binding site: Large, hydrophobic cavity with challenging BACE2 selectivity
- Key constraints: CNS penetration (MW <450, PSA <90A2), hERG (pIC50 <5)
- Structure quality: 1.8A resolution excellent for docking

**Screening Cascade**

Starting library: 2M compounds

**Stage 1: Property Filters (CPU: 2 hours)**

- Drug-likeness: MW <500, logP 1-4, HBD <3
- CNS MPO score >4 for brain penetration
- PAINS and aggregator removal
- Output: ~500K compounds (75% reduction)

**Stage 2: Shape-Based Screen (CPU: 8 hours)**

- ROCS similarity to known BACE1 inhibitor pharmacophores
- Select top 10% by TanimotoCombo scores
- Output: ~50K compounds

**Stage 3: Docking (GPU: 24 hours)**

- Glide SP mode against 1.8A crystal structure
- Rank by docking score with binding mode filter (catalytic dyad interaction)
- Select top 5,000 compounds
- Output: ~5,000 compounds

**Stage 4: ML Rescoring (GPU: 4 hours)**

- Graph neural network activity model trained on ChEMBL BACE1 data (8K compounds)
- ADMET-AI ensemble for hERG, PAMPA, metabolic stability
- Multi-objective Pareto ranking
- Output: 500 compounds

**Stage 5: Expert Review (40 hours)**

- Binding mode visualization in PyMOL
- Synthetic feasibility assessment (SA score, route complexity)
- IP landscape novelty check
- Output: 100 compounds for purchase/synthesis

**ML Model Strategy**

- Activity model: Message passing neural network on ChEMBL BACE1, 5-fold CV R2 >0.7
- hERG model: DeepChem classification, AUC >0.85
- PAMPA model: In-house random forest from historical data
- Metabolic stability: ADMET-AI ensemble prediction

**CNS Penetration Priorities**

- MW: 350-450 (target 400)
- PSA: 60-90A2 (target 75)
- HBD: 0-2 (target 1)
- cLogP: 2-4 (target 3)
- CNS MPO: >4.5

**Experimental Validation**

**Tier 1: Biochemical (100 compounds, ~$15K)**

- BACE1 FRET assay IC50 determination
- Hit criteria: IC50 <10 uM
- Expected: 15-25 hits (15-25% hit rate)

**Tier 2: Selectivity (25 compounds, ~$20K)**

- BACE2 selectivity assay (target >10x)
- Cathepsin D counter-screen
- hERG fluorescence polarization (IC50 >10 uM required)

**Tier 3: Permeability (15 compounds, ~$15K)**

- PAMPA-BBB assay
- MDR1-MDCK efflux ratio (<3 acceptable)
- Primary neuron toxicity assessment

**Tier 4: Lead Characterization (5-10 compounds, ~$30K)**

- Mouse PK with brain/plasma ratio determination
- Metabolite identification
- Off-target safety panel (50 targets)

**Timeline (24 weeks)**

- Weeks 1-2: Library preparation, ML model training
- Weeks 3-4: Virtual screening cascade execution
- Weeks 5-6: Expert review, compound procurement
- Weeks 7-10: Tier 1 biochemical screening
- Weeks 11-14: Tier 2-3 profiling
- Weeks 15-18: Tier 4 lead characterization
- Weeks 19-24: Hit expansion and SAR development

**Decision Gates**

- Gate 1 (Week 10): >15 hits with IC50 <10 uM - PROCEED
- Gate 2 (Week 14): >5 hits with BACE2 selectivity >10x and hERG IC50 >10 uM - PROCEED
- Gate 3 (Week 18): >2 leads with brain penetration (Kp,uu >0.3) - PROCEED to lead optimization

**Expected Outcomes**

- 15-25 validated hits from 100 tested (15-25% cascade hit rate)
- 5-10 selective, CNS-penetrant leads
- 2-3 chemical series for optimization
- Total program cost: ~$100K experimental + computational time

---

## Related Prompts

- [Clinical Trial Design Expert](../clinical-trial-design-and-optimization-expert.md) - Development planning
- [Predictive Toxicology Expert](predictive-toxicology-safety-assessment.md) - Safety assessment
- [Protein Structure Prediction](../bioinformatics/protein-structure-prediction-modeling.md) - Target modeling
